175553-32-9

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 175553-31-8 1-[2-(4-fluorophenyl)-ethyl]-piperidine-4-carboxylic acid ethyl ester 
• 332-42-3 (2-bromoethyl)-4-fluorobenzene 
• 7589-27-7 2-(4-Fluorophenyl)ethanol 

Downstream Products

• 252364-39-9 4-[1-oxo-1-(2,3-dimethoxyphenyl)methyl]-N-2-(4-fluorophenylethyl)piperidine 
• 175673-57-1 (-)-MDL 100907 
• 139290-69-0 (2,3-dimethoxy-phenyl)-{1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-methanol 
• 139290-65-6 R-(+)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol 
• 881897-59-2 {1-[2-(4-fluorophenyl)-ethyl]-piperidin-4-yl}(phenyl)methanone 
• 252364-41-3 [2-methoxy-3-[(1,1-dimethylethyldiphenylsilyl)oxy]phenyl][1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]methanone 

Relevant academic research and scientific papers

Total synthesis and evaluation of [18F]MHMZ

Radiochemical labeling of MDL 105725 using the secondary labeling precursor 2-[18F]fluoroethyltosylate ([18F]FETos) was carried out in yields of ～90% synthesizing [18F]MHMZ in a specific activity of ～50 MBq/nmol with a sta

The "reverse-tethered" ruthenium (II) catalyst for asymmetric transfer hydrogenation: Further applications

The attachment of a tethering group from the basic nitrogen atom to the arene ligand of a ruthenium(II) catalyst greatly improves its ability to catalyze asymmetric transfer hydrogenation (ATH) reactions. In this paper, we describe further applications of this versatile system to an extended substrate range.

Processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol"

The present invention provides various processes for the preparation of (R)-±-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by the following scheme:

An efficient synthesis of the precursors of [11C]MDL 100907 labeled in two specific positions

An efficient, integrated route for the synthesis of two precursors of [11C]MDL 100907 labeled in the 2'- or 3'-methoxy position is reported. The synthesis involved a one-pot, two-step process to transform the intermediate esters to ketones and subsequent resolution of the racemic alcohols to their respective enantiomers. The resolved, enantiomerically pure phenol precursors were reacted with high specific activity [11C]methyl iodide to produce [11C]MDL 100907 labeled in two specific positions.

Synthesis and preliminary in vivo evaluation of [11C]MDL 100907: A potent and selective radioligand for the 5-HT2A receptor system

11C-Labeled MDL 100907 and MDL 100009 were prepared by the reaction of [11C]CH3I with the corresponding phenol precursors. In vivo studies conducted in rats and a baboon demonstrated that intravenously injected [2-O[11C]CH3]MDL 100907 was regionally distributed in the brain in a manner consistent with the known distribution of 5-HT2A receptors. Injection of [2-O[11C]CH3]MDL 100009 resulted in a uniform brain distribution of radioactivity without regional localization consistent with the lower affinity of MDL 100009 for 5-HT2A receptors.